Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients

Cancer Cell

Volumn 29, Issue 4, 2016, Pages 587-601

  Halama, Niels ^a,b   Zoernig, Inka ^a   Berthel, Anna ^a,b   Kahlert, Christoph ^a,c   Klupp, Fee ^a   Suarez Carmona, Meggy ^a   Suetterlin, Thomas ^a,b   Brand, Karsten ^a   Krauss, Juergen ^a   Lasitschka, Felix ^a   Lerchl, Tina ^a,b   Luckner Minden, Claudia ^a   Ulrich, Alexis ^a   Koch, Moritz ^c   Weitz, Juergen ^c   Schneider, Martin ^a   Buechler, Markus W ^a   Zitvogel, Laurence ^d   Herrmann, Thomas ^e   Benner, Axel ^f   Kunz, Christina ^f   Luecke, Stephan ^f   Springfeld, Christoph ^a   Grabe, Niels ^a,b   Falk, Christine S ^g   Jaeger, Dirk ^a,b   more..

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Klinikum Idar Oberstein   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MARAVIROC; RANTES; REGORAFENIB; STAT3 PROTEIN; ALPHA INTERFERON; CARBANILAMIDE DERIVATIVE; CCL5 PROTEIN, HUMAN; CCR5 PROTEIN, HUMAN; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CLODRONIC ACID; CYCLOHEXANE DERIVATIVE; N(G) NITROARGININE METHYL ESTER; PYRIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN; TRIAZOLE DERIVATIVE; TUMOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; GOOD CLINICAL PRACTICE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; MIDDLE AGED; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PRIMARY CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; REPOLARIZATION; TREATMENT DURATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CHEMOTAXIS; COLORECTAL TUMOR; DRUG EFFECTS; IMMUNOLOGY; LIVER NEOPLASMS; LUNG NEOPLASMS; MACROPHAGE; METABOLISM; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PILOT STUDY; SECONDARY; SECRETION (PROCESS); SURVIVAL ANALYSIS; TUMOR CELL CULTURE; TUMOR INVASION;

ADENOCARCINOMA; APOPTOSIS; CHEMOKINE CCL5; CHEMOKINES; CHEMOTAXIS; CLINICAL TRIALS, PHASE I AS TOPIC; CLODRONIC ACID; COLORECTAL NEOPLASMS; CYCLOHEXANES; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NG-NITROARGININE METHYL ESTER; PHENYLUREA COMPOUNDS; PILOT PROJECTS; PYRIDINES; RECEPTORS, CCR5; STAT3 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TRIAZOLES; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84962698261     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.03.005     Document Type: Article

References (52)

1. Abel S., van der Ryst E., Rosario M.C., Ridgway C.E., Medhurst C.G., Taylor-Worth R.J., Muirhead G.J. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br. J. Clin. Pharmacol. 2008, 65(Suppl 1):5-18.
2. Acharyya S., Oskarsson T., Vanharanta S., Malladi S., Kim J., Morris P.G., Manova-Todorova K., Leversha M., Hogg N., Seshan V.E., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012, 150:165-178.
3. Affara N.I., Ruffell B., Medler T.R., Gunderson A.J., Johansson M., Bornstein S., Bergsland E., Steinhoff M., Li Y., Gong Q., et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 2014, 25:809-821.
4. Albini A., Benelli R. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat. Protoc. 2007, 2:504-511.
5. Arkenau H.T., Brunetto A.T., Barriuso J., Olmos D., Eaton D., de Bono J., Judson I., Kaye S. Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. Oncology 2009, 76:151-156.
6. Barashi N., Weiss I.D., Wald O., Wald H., Beider K., Abraham M., Klein S., Goldenberg D., Axelrod J., Pikarsky E., et al. Inflammation induced hepatocellular carcinoma is dependent on CCR5. Hepatology 2013, 58:1021-1030.
7. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339:286-291.
8. DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007, 9:212.
9. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
10. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., Mori J., Rickett G., Smith-Burchnell C., Napier C., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49:4721-4732.
11. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004, 22:329-360.
12. Ellis L.M., Fidler I.J. Finding the tumor copycat. Therapy fails, patients don't. Nat. Med. 2010, 16:974-975.
13. Findeisen P., Kloor M., Merx S., Sutter C., Woerner S.M., Dostmann N., Benner A., Dondog B., Pawlita M., Dippold W., et al. T25 repeat in the 3' untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res. 2005, 65:8072-8078.
14. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
15. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
16. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
17. Gonzalez-Martin A., Mira E., Manes S. CCR5 in cancer immunotherapy: more than an 'attractive' receptor for T cells. Oncoimmunology 2012, 1:106-108.
18. Grothey A., Van Cutsem E., Sobrero A., Siena S., Falcone A., Ychou M., Humblet Y., Bouche O., Mineur L., Barone C., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-312.
19. Halama N., Michel S., Kloor M., Zoernig I., Pommerencke T., von Knebel Doeberitz M., Schirmacher P., Weitz J., Grabe N., Jager D. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun. 2009, 9:1.
20. Halama N., Zoernig I., Spille A., Westphal K., Schirmacher P., Jaeger D., Grabe N. Estimation of immune cell densities in immune cell conglomerates: an approach for high-throughput quantification. PLoS One 2009, 4:e7847.
21. Halama N., Zoernig I., Spille A., Michel S., Kloor M., Grauling-Halama S., Westphal K., Schirmacher P., Jaeger D., Grabe N. Quantification of prognostic immune cell markers in colorectal cancer using whole slide imaging tumor maps. Anal Quant Cytol. Histol. 2010, 32:333-340.
22. Halama N., Braun M., Kahlert C., Spille A., Quack C., Rahbari N., Koch M., Weitz J., Kloor M., Zoernig I., et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin. Cancer Res. 2011, 17:678-689.
23. Halama N., Michel S., Kloor M., Zoernig I., Benner A., Spille A., Pommerencke T., von Knebel D.M., Folprecht G., Luber B., et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011, 71:5670-5677.
24. Halama N., Spille A., Lerchl T., Brand K., Herpel E., Welte S., Keim S., Lahrmann B., Klupp F., Kahlert C., et al. Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration. Oncoimmunology 2013, 2:e24116.
25. Hales R.K., Banchereau J., Ribas A., Tarhini A.A., Weber J.S., Fox B.A., Drake C.G. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann. Oncol. 2010, 21:1944-1951.
26. Hervas-Stubbs S., Perez-Gracia J.L., Rouzaut A., Sanmamed M.F., Le Bon A., Melero I. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 2011, 17:2619-2627.
27. Hwang W.L., Yang M.H., Tsai M.L., Lan H.Y., Su S.H., Chang S.C., Teng H.W., Yang S.H., Lan Y.T., Chiou S.H., et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 2011, 141:279-291. 291.e1-5.
28. Keim S., Zoernig I., Spille A., Lahrmann B., Brand K., Herpel E., Grabe N., Jager D., Halama N. Sequential metastases of colorectal cancer: Immunophenotypes and spatial distributions of infiltrating immune cells in relation to time and treatments. Oncoimmunology 2012, 1:593-599.
29. Klein C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9:302-312.
30. Kuang D.-M., Zhao Q., Peng C., Xu J., Zhang J.-P., Wu C., Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 2009, 206:1327-1337.
31. Lee Y., Chittezhath M., Andre V., Zhao H., Poidinger M., Biondi A., D'Amico G., Biswas S.K. Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10. Blood 2012, 119:227-237.
32. Liou G.Y., Doppler H., Necela B., Krishna M., Crawford H.C., Raimondo M., Storz P. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-kappaB and MMPs. J. Cell Biol. 2013, 202:563-577.
33. Melero I., Hervas-Stubbs S., Glennie M., Pardoll D.M., Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 2007, 7:95-106.
34. Mlecnik B., Tosolini M., Charoentong P., Kirilovsky A., Bindea G., Berger A., Camus M., Gillard M., Bruneval P., Fridman W.H., et al. Biomolecular network reconstruction identifies T cell homing factors associated with survival in colorectal cancer. Gastroenterology 2009, 138:1429-1440.
35. Musha H., Ohtani H., Mizoi T., Kinouchi M., Nakayama T., Shiiba K., Miyagawa K., Nagura H., Yoshie O., Sasaki I. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int. J. Cancer 2005, 116:949-956.
36. Nielsen D.L., Palshof J.A., Larsen F.O., Jensen B.V., Pfeiffer P. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. Cancer Treat Rev. 2014, 40:701-715.
37. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004, 16:1201-1210.
38. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
39. Qian B.Z., Pollard J.W. New tricks for metastasis-associated macrophages. Breast Cancer Res. 2012, 14:316.
40. Qin H., Holdbrooks A.T., Liu Y., Reynolds S.L., Yanagisawa L.L., Benveniste E.N. SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J. Immunol. 2012, 189:3439-3448.
41. Reshef R., Luger S.M., Hexner E.O., Loren A.W., Frey N.V., Nasta S.D., Goldstein S.C., Stadtmauer E.A., Smith J., Bailey S., et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N. Engl. J. Med. 2012, 367:135-145.
42. Sethi N., Kang Y. Unravelling the complexity of metastasis-molecular understanding and targeted therapies. Nat. Rev. Cancer 2011, 11:735-748.
43. Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., Vitale I., Goubar A., Baracco E.E., Remedios C., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 2014, 20:1301-1309.
44. Stewart T.J., Smyth M.J. Chemokine-chemokine receptors in cancer immunotherapy. Immunotherapy 2009, 1:109-127.
45. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 2012, 24:207-212.
46. Trinchieri G. Type I interferon: friend or foe?. J. Exp. Med. 2010, 207:2053-2063.
47. Van Cutsem E., Kohne C.-H., Hitre E., Zaluski J., Chang Chien C.-R., Makhson A., D'Haens G., Pinter T., Lim R., Bodoky G., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:1408-1417.
48. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 2012, 12:237-251.
49. Velasco-Velazquez M., Jiao X., De La Fuente M., Pestell T.G., Ertel A., Lisanti M.P., Pestell R.G. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012, 72:3839-3850.
50. Yan X., Orentas R.J., Johnson B.D. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine 2006, 33:188-198.
51. Zhou Q., Yan X., Gershan J., Orentas R.J., Johnson B.D. Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. J. Immunol. 2008, 181:1877-1886.
52. Zitvogel L., Apetoh L., Ghiringhelli F., Andre F., Tesniere A., Kroemer G. The anticancer immune response: indispensable for therapeutic success?. J. Clin. Invest. 2008, 118:1991-2001.